Search

Your search keyword '"Hemmelder, M. H."' showing total 27 results
Start Over Author "Hemmelder, M. H."
27 results on '"Hemmelder, M. H."'

1. De oudere met nierschade

Author

Joosten, J. M. H., Hemmelder, M. H., Kooman, J. P., Muris, J.W.M., editor, Schols, J.M.G.A., editor, Collet, J., editor, and Janssen, D.J.A., editor

Published
2023
Full Text
View/download PDF

3. Long-term efficacy and safety of SARS-CoV-2 vaccination in patients with chronic kidney disease, on dialysis or after kidney transplantation: a national prospective observational cohort study

Author

Bouwmans, P., Messchendorp, A. L., Sanders, J. S., Hilbrands, L., Reinders, M. E. J., Vart, P., Bemelman, F. J., Abrahams, A. C., van den Dorpel, M. A., Ten Dam, M. A., de Vries, A. P. J., Rispens, T., Steenhuis, M., Gansevoort, R. T., and Hemmelder, M. H.

Published
2022
Full Text
View/download PDF

4. Differences in mental health status during the COVID-19 pandemic between patients undergoing in-center hemodialysis and peritoneal dialysis.

Author

Bouwmans, Pim, Skalli, Zeinab, Vernooij, Robin W. M., Hemmelder, Marc H., Konijn, Wanda S., Lips, Joy, Mulder, Janneke, Bonenkamp, Anna A., van Jaarsveld, Brigit C., Abrahams, Alferso C., the DOMESTICO study group, Abrahams, A. C., Verhaar, M. C., van Jaarsveld, B. C., Dekker, F. W., van Ittersum, F. J., Konijn, W., Hemmelder, M. H., ten Dam, M. A. G. J., and van Eck van der Sluijs, A.

Published
2023
Full Text
View/download PDF

5. Recovery of dialysis patients with COVID-19: health outcomes 3 months after diagnosis in ERACODA

Author

Hemmelder, M. H., Noordzij, M., Vart, P., Hilbrands, L. B., Jager, K. J., Abrahams, A. C., Arroyo, D., Battaglia, Y., Ekart, R., Mallamaci, F., Malloney, S. -R., Oliveira, J., Rydzewski, A., Sridharan, S., Vogt, L., Duivenvoorden, R., Gansevoort, R. T., Franssen, C. F. M., van der Net, J. B., Essig, M., du Buf-Vereijken, P. W. G., van Ginneken, B., Maas, N., van Jaarsveld, B. C., Bemelman, F. J., Klingenberg-Salahova, F., Heenan-Vos, F., Vervloet, M. G., Nurmohamed, A., Abramowicz, D., Verhofstede, S., Maoujoud, O., Malfait, T., Fialova, J., Melilli, E., Fava, A., Cruzado, J. M., Perez, N. M., Lips, J., Krepel, H., Adilovic, H., Hengst, M., Konings, C. J. A. M., Braconnier, P., Weis, D., Gellert, R., Alferes, D. G., Radulescu, D., Zakharova, E. V., Ambuehl, P. M., Guidotti, R., Walker, A., Lepeytre, F., Rabate, C., Rostoker, G., Marques, S., Azasevac, T., Majstorovic, G. S., Katicic, D., Dam, M. T., Kruger, T., Brzosko, S., Liakopoulos, V., Zanen, A. L., Logtenberg, S. J. J., Fricke, L., Kuryata, O., Slebe, J. J. P., Abd ElHafeez, S., Kemlin, D., van de Wetering, J., Reinders, M. E. J., Hesselink, D. A., van Gestel, J. K., Eiselt, J., Kielberger, L., El-Wakil, H. S., Verhoeven, M. A. M., Logan, I., Canal, C., Facundo, C., Ramos, A. M., Debska-Slizien, A., Veldhuizen, N. M. H., Tigka, E., Polyzou Konsta, M. A., Panagoutsos, S., Postorino, A., Cambareri, F., Matceac, I., Nistor, I., Covic, A., Groeneveld, J. H. M., Jousma, J., Diekmann, F., Oppenheimer, F., Blasco, M., Pereira, T. A., dos Santos Junior, A. C. S., Arias-Cabrales, C., Crespo, M., Llinas-Mallol, L., Buxeda, A., Tarrega, C. B., Redondo-Pachon, D., Arenas Jimenez, M. D., Mendoza-Valderrey, A., Martins, A. C., Mateus, C., Alvila, G., Laranjinha, I., Hofstra, J. M., Siezenga, M. A., Franco, A., Castellano, S., Rodriguez-Ferrero, M. L., Manzanos, S. B., Haridian Sosa Barrios, R., Lemahieu, W., Bartelet, K., Dirim, A. B., Demir, E., Sever, M. S., Turkmen, A., Safak, S., Hollander, D. A. M. J., Kerckhoffs, A., Buttner, S., de Vries, A. P. J., Meziyerh, S., van der Helm, D., Mallat, M., Bouwsma, H., Petruliene, K., Verberk, I., van der Sande, F. M., Christiaans, M. H. L., Mohankumar, N., Luca, M. D., Tuglular, S. Z., Kramer, A., Beerenhout, C., Luik, P. T., Kerschbaum, J., Tiefenthaler, M., Watschinger, B., Adema, A. Y., Stepanov, V. A., Zulkarnaev, A. B., Turkmen, K., Gandolfini, I., Maggiore, U., Fliedner, A., Asberg, A., Mjoen, G., Miyasato, H., de Fijter, C. W. H., Mongera, N., Pini, S., de Biase, C., van de Logt, A. E., Maas, R., Lebedeva, O., Lopez, V., Reichert, L. J. M., Verhave, J., Titov, D., Parshina, E. V., Zanoli, L., Marcantoni, C., van Kempen, G., van Gils-Verrij, L. E. A., Harty, J. C., Meurs, M., Myslak, M., Lentini, P., den Deurwaarder, E., Stendahl, M., Rahimzadeh, H., Schouten, M., Rychlik, I., Cabezas-Reina, C. J., Roca, A. M., Nauta, F., Sahin, I., Goffin, E., Kanaan, N., Labriola, L., Devresse, A., Diaz-Mareque, A., Coca, A., de Arriba, G., Meijers, B. K. I., Naesens, M., Kuypers, D., Desschans, B., Tonnerlier, A., Wissing, K. M., Dedinska, I., Pessolano, G., Malik, S., Dounousi, E., Papachristou, E., Berger, S. P., Meijer, E., Sanders, J. S. F., Ozyilmaz, A., Ponikvar, J. B., Pernat, A. M., Kovac, D., Arnol, M., Molenaar, F. M., van Zuilen, A. D., Meijvis, S. C. A., Dolmans, H., Tantisattamo, E., Esposito, P., Krzesinski, J. -M., Barahira, J. D., Gallieni, M., Martin-Moreno, P. L., Guglielmetti, G., Guzzo, G., Toapanta, N., Soler, M. J., Luik, A. J., van Kuijk, W. H. M., Stikkelbroeck, L. W. H., Hermans, M. M. H., Rimsevicius, L., Righetti, M., Islam, M., Heitink-Ter Braak, N., Nephrology, ACS - Microcirculation, ACS - Diabetes & metabolism, UCL - SSS/IREC/NEFR - Pôle de Néphrologie, UCL - (SLuc) Service de néphrologie, Clinical sciences, Faculteit Medische Wetenschappen/UMCG, Groningen Kidney Center (GKC), Cardiovascular Centre (CVC), Groningen Institute for Organ Transplantation (GIOT), Interne Geneeskunde, RS: Carim - V02 Hypertension and target organ damage, Medical Informatics, APH - Aging & Later Life, APH - Quality of Care, APH - Global Health, ACS - Pulmonary hypertension & thrombosis, APH - Health Behaviors & Chronic Diseases, and Internal Medicine

Subjects
Male, Outcome Assessment, survival, mental health status, COVID-19 Testing, SDG 3 - Good Health and Well-being, Renal Dialysis, functional health status, Outcome Assessment, Health Care, 80 and over, Humans, KIDNEY-TRANSPLANT, AcademicSubjects/MED00340, Aged, Aged, 80 and over, Transplantation, SARS-CoV-2, MORTALITY, COVID-19, Middle Aged, Health Care, Intensive Care Units, Renal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11], Nephrology, dialysis, Original Article, Female, Renal disorders Radboud Institute for Health Sciences [Radboudumc 11]
Abstract

Background Coronavirus disease 2019 (COVID-19)-related short-term mortality is high in dialysis patients, but longer-term outcomes are largely unknown. We therefore assessed patient recovery in a large cohort of dialysis patients 3 months after their COVID-19 diagnosis. Methods We analyzed data on dialysis patients diagnosed with COVID-19 from 1 February 2020 to 31 March 2021 from the European Renal Association COVID-19 Database (ERACODA). The outcomes studied were patient survival, residence and functional and mental health status (estimated by their treating physician) 3 months after COVID-19 diagnosis. Complete follow-up data were available for 854 surviving patients. Patient characteristics associated with recovery were analyzed using logistic regression. Results In 2449 hemodialysis patients (mean ± SD age 67.5 ± 14.4 years, 62% male), survival probabilities at 3 months after COVID-19 diagnosis were 90% for nonhospitalized patients (n = 1087), 73% for patients admitted to the hospital but not to an intensive care unit (ICU) (n = 1165) and 40% for those admitted to an ICU (n = 197). Patient survival hardly decreased between 28 days and 3 months after COVID-19 diagnosis. At 3 months, 87% functioned at their pre-existent functional and 94% at their pre-existent mental level. Only few of the surviving patients were still admitted to the hospital (0.8–6.3%) or a nursing home (∼5%). A higher age and frailty score at presentation and ICU admission were associated with worse functional outcome. Conclusions Mortality between 28 days and 3 months after COVID-19 diagnosis was low and the majority of patients who survived COVID-19 recovered to their pre-existent functional and mental health level at 3 months after diagnosis.

Published
2022

6. Additional file 2 of Long-term efficacy and safety of SARS-CoV-2 vaccination in patients with chronic kidney disease, on dialysis or after kidney transplantation: a national prospective observational cohort study

Author

Bouwmans, P., Messchendorp, A. L., Sanders, J. S., Hilbrands, L., Reinders, M. E. J., Vart, P., Bemelman, F. J., Abrahams, A. C., van den Dorpel, M. A., Ten Dam, M. A., de Vries, A. P. J., Rispens, T., Steenhuis, M., Gansevoort, R. T., and Hemmelder, M. H.

Abstract

Additional file 2. Questionnaires at 6, 12 and 24 months after vaccination.

Published
2022
Full Text
View/download PDF

7. Additional file 1 of Long-term efficacy and safety of SARS-CoV-2 vaccination in patients with chronic kidney disease, on dialysis or after kidney transplantation: a national prospective observational cohort study

Author

Bouwmans, P., Messchendorp, A. L., Sanders, J. S., Hilbrands, L., Reinders, M. E. J., Vart, P., Bemelman, F. J., Abrahams, A. C., van den Dorpel, M. A., Ten Dam, M. A., de Vries, A. P. J., Rispens, T., Steenhuis, M., Gansevoort, R. T., and Hemmelder, M. H.

Abstract

Additional file 1. Questionnaire at 1 month after vaccination.

Published
2022
Full Text
View/download PDF

8. Clinical triage of patients on kidney replacement therapy presenting with COVID-19: An ERACODA registry analysis

Author

Mitra, S., Jayanti, A., Vart, P., Coca, A., Gallieni, M., Ovrehus, M. A., Midtvedt, K., Abd Elhafeez, S., Gandolfini, I., Buttner, S., Franssen, C. F. M., Hemmelder, M. H., Van Der Net, J. B., Essig, M., Du Buf-Vereijken, P. W. G., Van Ginneken, B., Maas, N., Vogt, L., Van Jaarsveld, B. C., Jager, K. J., Bemelman, F. J., Klingenberg-Salahova, F., Heenan-Vos, F., Vervloet, M. G., Nurmohamed, A., Abramowicz, D., Verhofstede, S., Maoujoud, O., Malfait, T., Fialova, J., Melilli, E., Fava, A., Cruzado, J. M., Perez, N. M., Lips, J., Krepel, H., Adilovic, H., Hengst, M., Rydzewski, A., Gellert, R., Oliveira, J., Alferes, D. G., Zakharova, E. V., Ambuehl, P. M., Walker, A., Winzeler, R., Lepeytre, F., Rabate, C., Rostoker, G., Marques, S., Azasevac, T., Katicic, D., Dam, M. T., Kruger, T., Brzosko, S., Zanen, A. L., Logtenberg, S. J. J., Fricke, L., Slebe, J. J. P., Kemlin, D., Van De Wetering, J., Reinders, M. E. J., Eiselt, J., Kielberger, L., El-Wakil, H. S., Verhoeven, M. A. M., Canal, C., Facundo, C., Ramos, A. M., Debska-Slizien, A., Veldhuizen, N. M. H., Tigka, E., Konsta, M. A. P., Panagoutsos, S., Mallamaci, F., Postorino, A., Cambareri, F., Covic, A., Matceac, I., Nistor, I., Cordos, M., Groeneveld, J. H. M., Jousma, J., Marjolijn Van Buren, Diekmann, F., Tiago Assis Pereira, Santos, A. C. S., Arias-Cabrales, C., Crespo, M., Llinas-Mallol, L., Buxeda, A., Tarrega, C. B., Redondo-Pachon, D., Jimenez, M. D. A., Hofstra, J. M., Franco, A., Arroyo, D., Rodriguez-Ferrero, M. L., Manzanos, S. B., Barrios, R. H. S., Avila, G., Laranjinha, I., Mateus, C., Lemahieu, W., Bartelet, K., Dirim, A. B., Sever, M. S., Demir, E., Safak, S., Turkmen, A., Hollander, D. A. M. J., De Vries, A. P. J., Meziyerh, S., Van Der Helm, D., Mallat, M., Bouwsma, H., Sridharan, S., Petruliene, K., Maloney, S. -R., Verberk, I., Van Der Sande, F. M., Christiaans, M. H. L., Mohankumar, N., Di Luca, M., Tuglular, S. Z., Kramer, A., Beerenhout, C., Luik, P. T., Kerschbaum, J., Tiefenthaler, M., Watschinger, B., Adema, A. Y., Stepanov, V. A., Zulkarnaev, A. B., Turkmen, K., Fliedner, A., Asberg, A., Mjoen, G., Miyasato, H., De Fijter, C. W. H., Mongera, N., Pini, S., De Biase, C., Duivenvoorden, R., Hilbrands, L., Kerckhoffs, A., Van De Logt, A. -E., Maas, R., Lebedeva, O., Lopez, V., Verhave, J., Reichert, L. J. M., Titov, D., Parshina, E. V., Zanoli, L., Marcantoni, C., Van Gils-Verrij, L. E. A., Harty, J. C., Meurs, M., Myslak, M., Battaglia, Y., Lentini, P., Den Deurwaarder, E., Stendahl, M., Rahimzadeh, H., Schouten, M., Rychlik, I., Cabezas-Reina, C. J., Roca, A. M., Nauta, F., Goffin, E., Kanaan, N., Labriola, L., Devresse, A., Diaz-Mareque, A., Meijers, B. K. I., Naesens, M., Kuypers, D., Desschans, B., Tonnelier, A., Wissing, K. M., De Arriba, G., Dedinska, I., Pessolano, G., Maggiore, U., Malik, S., Papachristou, E., Gansevoort, R. T., Noordzij, M., Berger, S. P., Meijer, E., Ozyilmaz, A., Sanders, J. S. F., Ponikvar, J. B., Arnol, M., Pernat, A. M., Kovac, D., Ekart, R., Abrahams, A. C., Molenaar, F. M., Van Zuilen, A. D., Meijvis, S. C. A., Dolmans, H., Tantisattamo, E., Esposito, P., Krzesinski, J. -M., Barahira, J. D., Sabiu, G., Martin-Moreno, P. L., Guglielmetti, G., Guzzo, G., Toapanta, N., Soler, M. J., Luik, A. J., Van Kuijk, W. H. M., Stikkelbroeck, L. W. H., Hermans, M. M. H., Rimsevicius, L., Righetti, M., Islam, M., Braak, N. H. -T., Nephrology, UCL - SSS/IREC/NEFR - Pôle de Néphrologie, UCL - (SLuc) Service de néphrologie, Interne Geneeskunde, RS: Carim - V02 Hypertension and target organ damage, Groningen Kidney Center (GKC), ACS - Diabetes & metabolism, AII - Inflammatory diseases, AII - Infectious diseases, Internal Medicine, and Clinical sciences

Subjects
kidney, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), medicine.medical_treatment, Pulmonary insufficiency, infectious diseases, Kidney, Second presentation, Interquartile range, Internal medicine, medicine, Humans, Registries, Mortality, AcademicSubjects/MED00340, Dialysis, Aged, Transplantation, second presentation, business.industry, SARS-CoV-2, COVID-19, medicine.disease, mortality, Triage, Hospitalization, Renal Replacement Therapy, Renal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11], Nephrology, Oxygen Saturation, dialysis, Original Article, Hemodialysis, Renal disorders Radboud Institute for Health Sciences [Radboudumc 11], Presentation (obstetrics), business, transplantation
Abstract

Background Patients on kidney replacement therapy (KRT) are at very high risk of coronavirus disease 2019 (COVID-19). The triage pathway for KRT patients presenting to hospitals with varying severity of COVID-19 illness remains ill-defined. We studied the clinical characteristics of patients at initial and subsequent hospital presentations and the impact on patient outcomes. Methods The European Renal Association COVID-19 Database (ERACODA) was analysed for clinical and laboratory features of 1423 KRT patients with COVID-19 either hospitalized or non-hospitalized at initial triage and those re-presenting a second time. Predictors of outcomes (hospitalization, 28-day mortality) were then determined for all those not hospitalized at initial triage. Results Among 1423 KRT patients with COVID-19 [haemodialysis (HD), n = 1017; transplant, n = 406), 25% (n = 355) were not hospitalized at first presentation due to mild illness (30% HD, 13% transplant). Of the non-hospitalized patients, only 10% (n = 36) re-presented a second time, with a 5-day median interval between the two presentations (interquartile range 2–7 days). Patients who re-presented had worsening respiratory symptoms, a decrease in oxygen saturation (97% versus 90%) and an increase in C-reactive protein (26 versus 73 mg/L) and were older (72 vs 63 years) compared with those who did not return a second time. The 28-day mortality between early admission (at first presentation) and deferred admission (at second presentation) was not significantly different (29% versus 25%; P = 0.6). Older age, prior smoking history, higher clinical frailty score and self-reported shortness of breath at first presentation were identified as risk predictors of mortality when re-presenting after discharge at initial triage. Conclusions This study provides evidence that KRT patients with COVID-19 and mild illness can be managed effectively with supported outpatient care and with vigilance of respiratory symptoms, especially in those with risk factors for poor outcomes. Our findings support a risk-stratified clinical approach to admissions and discharges of KRT patients presenting with COVID-19 to aid clinical triage and optimize resource utilization during the ongoing pandemic.

Published
2021

9. The RECOVAC IR study: the immune response and safety of the mRNA-1273 COVID-19 vaccine in patients with chronic kidney disease, on dialysis or living with a kidney transplant

Author

Kho, Marcia M. L., Reinders, Marlies E. J., Baan, Carla C., van Baarle, Debbie, Bemelman, Frederike J., DIavatopoulos, D. Imitri A., Gansevoort, Ron T., van der Klis, Fiona R. M., Koopmans, Marion P. G., Messchendorp, A. Lianne, van der Molen, Renate G., Remmerswaal, Ester B. M., Rots, Nynke, Vart, Priya, de Vries, Rory D., Hilbrands, Luuk B., Sanders, Jan-Stephan F., Abrahams, A. C., Hemmelder, M. H., ten Dam, M. A. G. J., de Vries, A. P. J., van Binnendijk, R. S., den Hartog, G., Bouwmans, P., Frolke, S., Malahé, S. R. K., Translational Immunology Groningen (TRIGR), Groningen Kidney Center (GKC), Cardiovascular Centre (CVC), Groningen Institute for Organ Transplantation (GIOT), Nephrology, AII - Inflammatory diseases, Experimental Immunology, APH - Aging & Later Life, Internal Medicine, and Virology

Subjects
Chronic/complications, medicine.medical_specialty, COVID-19 Vaccines, Renal Insufficiency, Chronic/complications, medicine.medical_treatment, COVID-19/prevention & control, lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4], Kidney Failure, Immune system, SDG 3 - Good Health and Well-being, Renal Dialysis, Internal medicine, Research Letter, medicine, Humans, Renal Insufficiency, Renal Insufficiency, Chronic, AcademicSubjects/MED00340, Vaccines, Synthetic/adverse effects, Dialysis, Kidney transplantation, Vaccines, Transplantation, Vaccines, Synthetic, business.industry, Immunity, COVID-19, medicine.disease, Kidney Transplantation, Chronic/therapy, Vaccination, Kidney Failure, Chronic/therapy, Nephrology, Cohort, Kidney Failure, Chronic, Observational study, Hemodialysis, Renal disorders Radboud Institute for Health Sciences [Radboudumc 11], business, Synthetic/adverse effects, Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5], Kidney disease, 2019-nCoV Vaccine mRNA-1273, COVID-19 Vaccines/adverse effects
Abstract

Contains fulltext : 237509.pdf (Publisher’s version ) (Open Access)

Published
2021

10. COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration

Author

Hilbrands, L. B., Duivenvoorden, R., Vart, P., Franssen, C. F. M., Hemmelder, M. H., Jager, K. J., Kieneker, L. M., Noordzij, M., Pena, M. J., de Vries, H., Arroyo, D., Covic, A., Crespo, M., Goffin, E., Islam, M., Massy, Z. A., Montero, N., Oliveira, J. P., Munoz, A. R., Sanchez, J. E., Sridharan, S., Winzeler, R., Gansevoort, R. T., van der Net, Jeroen B., Marie, Essig, Peggy W, G du Buf-Vereijken, Betty van Ginneken, Nanda, Maas, Liffert, Vogt, van Jaarsveld, Birgit C., Bemelman, Frederike J., Farah, Klingenberg-Salahova, Frederiek, Heenan-Vos, Vervloet, Marc G., Azam, Nurmohamed, Daniel, Abramowicz, Sabine, Verhofstede, Omar, Maoujoud, Jana, Fialova, Edoardo, Melilli, Alex, Favà, Cruzado, Josep M., Joy, Lips, Maaike, Hengst, Ryszard, Gellert, Andrzej, Rydzewski, Alferes, Daniela G., Ivan, Rychlik, Zakharova, Elena V., Patrice Max Ambuehl, Fanny, Lepeytre, Clémentine, Rabaté, Guy, Rostoker, Sofia, Marques, Tijana, Azasevac, Dajana, Katicic, Marc ten Dam, Thilo, Krüger, Susan J, J Logtenberg, Lutz, Fricke, L van Zanen, A, Jeroen J, P Slebe, Delphine, Kemlin, Jacqueline van de Wetering, Jaromir, Eiselt, Lukas, Kielberger, El-Wakil, Hala S., Samar Abd ElHafeez, Christina, Canal, Carme, Facundo, Ramos, Ana M., Alicja, Debska-Slizien, Nicoline M, H Veldhuizen, Stylianos, Panagoutsos, Irina, Matceac, Ionut, Nistor, Monica, Cordos, J H, M Groeneveld, Marjolijn van Buren, Fritz, Diekmann, Ferreira, Ana C., Augusto Cesar, S. Santos Jr., Carlos, Arias-Cabrales, Laura, Llinàs-Mallol, Anna, Buxeda, Carla Burballa Tàrrega, Dolores, Redondo-Pachon, Maria Dolores Arenas Jimenez, Hofstra, Julia M., Antonio, Franco, Rodríguez-Ferrero, María L., Sagrario Balda Manzanos, Gabriel de Arriba, Haridian Sosa Barrios, R., Karlijn, Bartelet, Erol, Demir, Daan A M, J Hollander, Angele, Kerckhoffs, Stefan, Büttner, Aiko P, J de Vries, Soufian, Meziyerh, Danny van der Helm, Marlies, Reinders, Hanneke, Bouwsma, Kristina, Petruliene, Sharon, Maloney, Iris, Verberk, Marina Di Luca, Tuğlular, Serhan Z., Charles, Beerenhout, Luik, Peter T., Julia, Kerschbaum, Martin, Tiefenthaler, Bruno, Watschinger, Adema, Aaltje Y., Stepanov, Vadim A., Zulkarnaev, Alexey B., Kultigin, Turkmen, Bonucchi, Decenzio, Anselm, Fliedner, Hitoshi, Miyasato, Anders, Åsberg, Geir, Mjoen, Stefano, Pini, Consuelo de Biase, Anne Els van de Logt, Rutger, Maas, Olga, Lebedeva, Veronica, Lopez, Louis J, M Reichert, Jacobien, Verhave, Denis, Titov, Parshina, Ekaterina V., Liesbeth E, A van Gils-Verrij, Charlotte J, R de Bruin, Harty, John C., Marleen, Meurs, Marek, Myslak, Yuri, Battaglia, Paolo, Lentini, Edwin den Deurwaarder, Hormat, Rahimzadeh, Marcel, Schouten, Cabezas-Reina, Carlos J., Anabel, Diaz-Mareque, Armando, Coca, Björn K, I Meijers, Maarten, Naesens, Dirk, Kuypers, Bruno, Desschans, Annelies, Tonnerlier, Wissing, Karl M., Ivana, Dedinska, Giuseppina, Pessolano, van der Sande, Frank M., Maarten H, L Christiaans, Ilaria, Gandolfini, Umberto, Maggiore, Nada, Kanaan, Laura, Labriola, Arnaud, Devresse, Shafi, Malik, Berger, Stefan P., Esther, Meijer, Sanders, Jan Stephan F., Jadranka Buturović Ponikvar, Abrahams, Alferso C., Molenaar, Femke M., van Zuilen, Arjan D., S C, A Meijvis, Helma, Dolmans, Luca, Zanoli, Carmelita, Marcantoni, Esposito, Pasquale, Jean-Marie, Krzesinski, Jean Damacène Barahira, Maurizio, Gallieni, Gianmarco, Sabiu, Paloma Leticia Martin-Moreno, Gabriele, Guglielmetti, Gabriella, Guzzo, Luik, Antinus J., Willi H, M van Kuijk, Lonneke W, H Stikkelbroeck, Hermans, Marc M. H., Laurynas, Rimsevicius, Marco, Righetti, Nicole Heitink-ter Braak, UCL - SSS/IREC/NEFR - Pôle de Néphrologie, UCL - (SLuc) Service de néphrologie, Groningen Kidney Center (GKC), Cardiovascular Centre (CVC), Clinical sciences, Nephrology, Medical Informatics, ACS - Pulmonary hypertension & thrombosis, APH - Aging & Later Life, APH - Global Health, and APH - Quality of Care

Subjects
Male, Databases, Factual, Kidney Failure, Chronic/mortality, medicine.medical_treatment, 030232 urology & nephrology, Waiting Lists/mortality, Kidney Failure, 0302 clinical medicine, Risk Factors, Epidemiology, Kidney Transplantation/mortality, 80 and over, Medicine, 030212 general & internal medicine, Prospective Studies, Chronic, Prospective cohort study, Kidney transplantation, Aged, 80 and over, Renal Dialysis/mortality, SARS-CoV-2/isolation & purification, Hazard ratio, Age Factors, Middle Aged, Prognosis, Europe, Survival Rate, Nephrology, COVID-19, Dialysis, Kidney, Mortality, Transplantation, Adult, Aged, Female, Humans, Kidney Failure, Chronic, Kidney Transplantation, Renal Dialysis, SARS-CoV-2, Waiting Lists, Hemodialysis, medicine.medical_specialty, kidney, Europe/epidemiology, 03 medical and health sciences, Databases, All institutes and research themes of the Radboud University Medical Center, Internal medicine, AcademicSubjects/MED00340, Survival rate, Factual, COVID-19/chemically induced, business.industry, Original Articles, medicine.disease, mortality, Renal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11], dialysis, Renal disorders Radboud Institute for Health Sciences [Radboudumc 11], business, transplantation
Abstract

Background. Patients on kidney replacement therapy comprise a vulnerable population and may be at increased risk of death from coronavirus disease 2019 (COVID-19). Currently, only limited data are available on outcomes in this patient population. Methods. We set up the ERACODA (European Renal Association COVID-19 Database) database, which is specifically designed to prospectively collect detailed data on kidney transplant and dialysis patients with COVID-19. For this analysis, patients were included who presented between 1 February and 1 May 2020 and had complete information available on the primary outcome parameter, 28-day mortality. Results. Of the 1073 patients enrolled, 305 (28%) were kidney transplant and 768 (72%) dialysis patients with a mean age of 60 ± 13 and 67 ± 14 years, respectively. The 28-day probability of death was 21.3% [95% confidence interval (95% CI) 14.3–30.2%] in kidney transplant and 25.0% (95% CI 20.2–30.0%) in dialysis patients. Mortality was primarily associated with advanced age in kidney transplant patients, and with age and frailty in dialysis patients. After adjusting for sex, age and frailty, in-hospital mortality did not significantly differ between transplant and dialysis patients [hazard ratio (HR) 0.81, 95% CI 0.59–1.10, P = 0.18]. In the subset of dialysis patients who were a candidate for transplantation (n = 148), 8 patients died within 28 days, as compared with 7 deaths in 23 patients who underwent a kidney transplantation Conclusions. The 28-day case-fatality rate is high in patients on kidney replacement therapy with COVID-19 and is primarily driven by the risk factors age and frailty. Furthermore, in the first year after kidney transplantation, patients may be at increased risk of COVID-19-related mortality as compared with dialysis patients on the waiting list for transplantation. This information is important in guiding clinical decision-making, and for informing the public and healthcare authorities on the COVID-19-related mortality risk in kidney transplant and dialysis patients.

Published
2020
Full Text
View/download PDF

11. Abstracts of papers and posters

Author

Anthonio, R. L., Willemsen, A. T. M., Visser, T., van Waarde, A., Elzinga, P., Weemaes, A., Meeder, J. G., Pruim, J., Visser, G., Blanksma, P. K., Vaalburg, W., Bloemen, P. G. M., Henricks, P. A. J., van Bloois, L., van den Tweel, M. C., Nijkamp, F. P., Crommelin, D. J. A., Storm, G., de Boer, A. H., Winter, H. M. I., Lerk, C. F., de Boer, J., Meurs, H., Bottone, A. E., Koopal, M., Visser, J. C., Zaagsma, J., Borger P., Kauffman H. F., Vijgen J. L. J., Postma D. S., Vellenga E., Buckley, Theresa L., Buikema, H., van Gilst, W. H., van Veldhuisen, D. J., de Smet, B. J. G. L., Scholtens, E., Lie, K. I., Wesseling, H., Cheung, P. K., Dijkhuis, F. W. D., Bakker, W. W., Visser, J., Coopes, R. P., Benthem, L., van der Leest, J., Roffel, A. F., Coppes, R. P., Zeilstra, L. J. W., Vissink, A., Konings, A. W. T., Dijkstra, M., Veld, G. In't, Müller, M., van den Berg, G. J., Kuipers, F., Vonk, R. J., Elsinga, P. H., Franssen, E. J. F., van der Graaf, W. T. A., de Vries, E. G. E., Visser, G. M., Vos, M. G., Braker, A. H., Visser, T. J., Visser, G. M., Engels, F., van Houwelingen, A. H., van de Velde, M. J., Gansevoort, R. T., Sluiter, W. J., Hemmelder, M. H., de Zeeuw, D., de Jong, P. E., Gelissen, H. P. M. M., Henning, R. H., Epema, A. H., van Eekeren, J., Hennis, P. J., Den Hertog, A., de Graaf, S. S. N., Kellie, S. J., Bloemhof, H., Johnston, I., Besser, M., Chaseling, R. W., Ouvrier, R. A., Uqes, D. R. A., De Haan, A., Geerligs, H. J., Huchshorn, J. P., Van Scharenburg, G. J. M., Wilschut, J., Haas, M., Kluppel, C. A., Meijer, D. K. F., Moolenaar, F., Heerdink, Eibert R., Leufkens, Hubert G., Herings, Ron M. C., Stricker, Bruno H. Ch., Bakker, Albert, Heesen W. F., Beltman F. W., Smit A. J., May J. F., Meyboom-de Jong B., Duin, M., van den Akker, J., te Pas, M. F. W., van Popta, J. P., Nelemans, S. A., van der Linde, H. J., de Boer, A., Sturmans, F., Hessel, E. M., Van Oosterhout, A. J. M., Hofstra, C. L., Garssen, J., van Loveren, H., Savelkoul, H. F. J., Hoekstra, Y., Weersink, E. J. M., de Jong, J. W., van der Belt-Gritter, B., Jonkman, Lisa M., Kemner, Chantal, Koelega, Harry S., van Engeland, Herman, Verbaten, Marinus N., Kalivianakis, M., Zijlstra, I., Verkade, H. J., Elzinga, H., Stellaard, F., Kamps, J. A. A. M., Swart, P. J., Morselt, H., Scherphof, G. L., Kenemans, J. L., Lorist, M. M., Koopen, N. R., Kraneveld, A. D., Koster, A. Si., Kuipers, M. E., Groenink, M., Huisman, H., Schuitemaker, H., Lau, H. S., van den Broek, I. J. P. M., van Dijk, A., Oostinga, J., Porsius, A. J., Lin, Y., Havinga, R., Meijer, R. J., van der Mark, Th. W., Koëter, G. H., Michels, A. A., Nguyen, V. -T., Bensaude, O., Kampinga, H. H., Mohede, Inge C. M., Van Antoon J. M., Molema, Grietje, Edgington, Thomas S., Thorpe, Philip E., Olinga, P., Sandker, G. W., Slooff, M. J. H., Merema, M. T., Groothuis, G. M. M., Hofman, G., Van Ark, I., Paulussen, J. J. C., Fischer, M. J. E., de Mol, N. J., Janssen, L. H. M., Peters, E. Th. J., van der Werf, G. Th., Haaijer-Ruskamp, F. M., Pinto, Yigal M., Rooks, Gerrit, Grandjean, Jean G., Ebels, Tjark, Schunkert, H., Redegeld, Frank A., Garssen, Johan, van Loveren, Henk, Rigter, Irma M., van Groningen, Muck, Boks, Gertjan J., Tollenaere, Jan P., Trollope, Keith I., Vinter, Jeremy G., Hashjin, Gudarz Sadeghi, Folkerts, Gert, van de Loo, Peet G. F., Santing, R. E., Olymulder, C. G., van der Molen, K., Pasman, Y., Scheerens, Heleen, Van Loveren, Henk, Seppenwoolde-Waasdorp, T. J. A., de Boer, P., Van Engelen, H. M. J., Thijssen, J. H. H., Maes, R. A. A., Smit, J., Smit, J. W., Steen, H., Steurs, M. H., Kuks, P. F. M., Leusink, J. A., Szabó, Balázs M., Crijns, Harry J. G. M., Wiesfeld, Ans C. P., Talsma, H., Borchert, J. C. H., van Steenbergen, M. J., Hennink, W. E., Teeuw, K. B., Cromheecke, H., Schreudering, A., Teisman, B. C. H., Maselbas, W., Wolters-Keulemans, G. T. P., Tieleman, R. G., de Langen, C. D. J., Bel, K., Crijns, H. J. G. M., Grandjean, J., Wijffels, M., Klimp, A. H., van de Meer, P. F., Allessie, M. A., van Patot, H. A. Tissot, de Jongh, B. M., Tuininga, Y. S., Brouwer, J., Haaksma, J., Man in't Veld, A. J., Blomjous, F. J., Vingerhoeds, M. H., Belliot, S. O., Haisma, H. J., Visscher, C. A., Huisman, R. M., Navis, G. J., de Vlieger, J. F., van den Wijngaard, P., Wilting, J., van Heuven-Nolsen, D., Voors, A. A., van Brussel, B. L., Plokker, H. W. M., Van Waardenburg R. C. A. M., Meijer, Prins J., De Vries, C., Mulder N. H., Wierenga, P. K., Wilschut J., Schoen P., and Bron R.

Published
1994
Full Text
View/download PDF

12. Reply

Author

Slagman, M. C. J., primary, Sinkeler, S. J., additional, Hemmelder, M. H., additional, Waanders, F., additional, Vogt, L., additional, Kluin-Nelemans, H. C., additional, Navis, G., additional, and Laverman, G. D., additional

Published
2010
Full Text
View/download PDF

14. Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials.

Author

Gansevoort, R. T., Sluiter, W. J., Hemmelder, M. H., de Zeeuw, D., and de Jong, P. E.

Abstract

Whether ACE inhibitors (ACEi) differ from other antihypertensives in their efficacy to lower proteinuria is controversial. We therefore performed a meta-analysis of articles on this subject. The secondary objective in our meta-analysis was to study whether there is any difference between diabetic and non-diabetic patients in antiproteinuric response to blood pressure reduction. To identify all articles we performed a computer search using the bibliographic databases. To minimize publication bias, only trials in which a direct comparison was made between an ACEi and another antihypertensive were included. Studies performed both in diabetic and in non-diabetic patients were eligible. Included were 41 studies, comprising 1124 patients, of which 558 had non-diabetic renal disease. The mean antiproteinuric effect of ACEi was significantly greater than that of their comparator drugs: −39.9% (95% confidence interval: −42.8 to −36.8%) versus −17.0% (−19.0 to −15.1%) respectively (difference 24% (19.5 to 28.6%)). The blood-pressure-lowering effect was equal: −12.0% (−12.8 to −11.2%) versus −11.4% (−11.7 to −11.1%) respectively (difference −0.8% (−1.8 to 0.2%)). Thus it may be concluded that ACEIs confer an antiproteinuric effect beyond that attributable to their blood-pressure-lowering effect. A wide interstudy variation in antiproteinuric response to non-ACEI antihypertensives was observed. Multiple variable regression analysis was performed to assess which factors may explain this heterogeneity. From the comparator drugs, the class was of no importance: calcium-channel antagonists (CCA), β-blockers, and a rest group of other drug types showed a similar response. Patient characteristics such as initial GFR and blood pressure partly explained the variation in response, but most of it appeared dependent on the blood pressure reduction achieved. Furthermore the type of CCA is of importance, with nifedipine having the least effect. A significantly greater antiproteinuric effect of ‘non-ACEI’ antihypertensives was found in diabetic patients compared to non-diabetics. However, this coincided with a greater blood pressure reduction in diabetics. Adjusted for differences in blood pressure control, diabetics showed even a slightly lesser antiproteinuric response to non-ACEI antihypertensive compared to non-diabetics. [ABSTRACT FROM PUBLISHER]

Published
1995

16. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide.

Author

Buter, H, Hemmelder, M H, Navis, G, de Jong, P E, and de Zeeuw, D

Abstract

Dietary sodium restriction enhances the antiproteinuric and blood pressure lowering effect of ACE inhibition. In clinical practice, however, long-term compliance to a low-sodium diet may be difficult to obtain. We therefore investigated whether the blunting of the antiproteinuric and blood pressure lowering efficacy of ACE inhibition by high sodium intake can be restored by the addition of a diuretic.

Published
1998
Full Text
View/download PDF

17. Safety and long-term effects of renal denervation: Rationale and design of the Dutch registry

Author

Sanders, M. F., Blankestijn, P. J., Voskuil, M., Spiering, W., Vonken, E. J., Rotmans, J. I., Hoeven, B. L., Daemen, J., Den Meiracker, A. H., Kroon, A. A., Haan, M. W., Das, M., Bax, M., Meer, I. M., Overhagen, H., Den Born, B. J. H., Brussel, P. M., Valk, P. H. M., Gregoor, P. J. H. Smak, Meuwissen, M., Gomes, M. E. R., Ophuis, T. Oude, Troe, E., Tonino, W. A. L., Konings, C. J. A. M., Vries, P. A. M., Balen, A., Heeg, J. E., johannes smit, Elvan, A., Steggerda, R., Niamut, S. M. L., Peels, J. O. J., Swart, J. B. R. M., Wardeh, A. J., Groeneveld, J. H. M., Linden, E., Hemmelder, M. H., Folkeringa, R., Stoel, M. G., Kant, G. D., Herrman, J. P. R., Wissen, S., Deinum, J., Westra, S. W., Aengevaeren, W. R. M., Parlevliet, K. J., Schramm, A., Jessurun, G. A. J., Rensing, B. J. W. M., Winkens, M. H. M., Wierema, T. K. A., Santegoets, E., Lipsic, E., Houwerzijl, E., Kater, M., Allaart, C. P., Nap, A., Bots, M. L., AII - Infectious diseases, General practice, Molecular cell biology and Immunology, Internal medicine, Pediatric surgery, Cardiology, Surgery, ICaR - Circulation and metabolism, Interne Geneeskunde, MUMC+: MA Alg Interne Geneeskunde (9), RS: CARIM - R3.02 - Hypertension and target organ damage, Beeldvorming, MUMC+: DA Beeldvorming (5), MUMC+: DA BV Medisch Specialisten Radiologie (9), RS: CARIM - R3.11 - Imaging, Other departments, Vascular Medicine, and Internal Medicine

Subjects
Male, hypertension, Vascular damage Radboud Institute for Health Sciences [Radboudumc 16], CONTROLLED-TRIAL, GLOBAL SYMPLICITY REGISTRY, DISEASE, Time, BLOOD-PRESSURE CHANGES, Renal Artery, Kidney function, cardiovascular disease, Internal Medicine, Humans, Prospective Studies, Registries, Sympathectomy, kidney function, renal denervation, Antihypertensive Agents, Aged, Netherlands, Middle Aged, Cardiovascular disease, MODEL, Treatment Outcome, Preoperative Period, Hypertension, SYMPATHETIC DENERVATION, Blood pressure, Renal denervation, TREATMENT-RESISTANT HYPERTENSION, Female, SYSTEM, PROGNOSTIC RESEARCH
Abstract

Item does not contain fulltext BACKGROUND: Percutaneous renal denervation (RDN) has recently been introduced as a treatment for therapyresistant hypertension. Also, it has been suggested that RDN may be beneficial for other conditions characterised by increased sympathetic nerve activity. There are still many uncertainties with regard to efficacy, safety, predictors for success and long-term effects. To answer these important questions, we initiated a Dutch RDN registry aiming to collect data from all RDN procedures performed in the Netherlands. METHODS: The Dutch RDN registry is an ongoing investigator-initiated, prospective, multicentre cohort study. Twenty-six Dutch hospitals agreed to participate in this registry. All patients who undergo RDN, regardless of the clinical indication or device that is used, will be included. Data are currently being collected on eligibility and screening, treatment and follow-up. RESULTS: Procedures have been performed since August 2010. At present, data from 306 patients have been entered into the database. The main indication for RDN was hypertension (n = 302, 99%). Patients had a mean office blood pressure of 177/100 (±29/16) mmHg with a median use of three (range 0-8) blood pressure lowering drugs. Mean 24-hour blood pressure before RDN was 157/93 (±18/13) mmHg. RDN was performed with different devices, with the Simplicity™ catheter currently used most frequently. CONCLUSION: Here we report on the rationale and design of the Dutch RDN registry. Enrolment in this investigator-initiated study is ongoing. We present baseline characteristics of the first 306 participants.

19. Strategies to prevent SARS-CoV-2 transmission in hemodialysis centres across Europe—lessons for the future

Author

Noordzij, Marlies, Meijers, Björn, Gansevoort, Ron T, Covic, Adrian, Duivenvoorden, Raphaël, Hilbrands, Luuk B, Hemmelder, Marc H, Jager, Kitty J, Mjoen, Geir, Nistor, Ionut, Parshina, Ekaterina, Pessolano, Giuseppina, Tuglular, Serhan, Vart, Priya, Zanoli, Luca, Franssen, Casper F M, ERACODA collaborators, Goffin, Eric, Kanaan, Nada, Labriola, Laura, Devresse, Arnaud, UCL - SSS/IREC/NEFR - Pôle de Néphrologie, UCL - (SLuc) Service de néphrologie, and Noordzij M., Meijers B., Gansevoort R. T., Covic A., Duivenvoorden R., Hilbrands L. B., Hemmelder M. H., Jager K. J., Mjoen G., Nistor I., et al.

Subjects
Internal Diseases, Urology, Sağlık Bilimleri, İç Hastalıkları, Clinical Medicine (MED), All institutes and research themes of the Radboud University Medical Center, UROLOGY & NEPHROLOGY, Health Sciences, Klinik Tıp (MED), KIDNEY-TRANSPLANT, guidelines, ÜROLOJİ VE NEFROLOJİ, Transplantation, Internal Medicine Sciences, Science & Technology, hemodialysis, Klinik Tıp, SARS-CoV-2, MORTALITY, Dahili Tıp Bilimleri, centre practices, CLINICAL MEDICINE, Urology & Nephrology, virus transmission, Tıp, DIALYSIS PATIENTS, Renal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11], Nefroloji, Nephrology, ERACODA, Üroloji, Medicine, Renal disorders Radboud Institute for Health Sciences [Radboudumc 11], Life Sciences & Biomedicine
Abstract

Background Early reports on the pandemic nature of coronavirus disease 2019 (COVID-19) directed the nephrology community to develop infection prevention and control (IPC) guidance. We aimed to make an inventory of strategies that dialysis centres followed to prevent infection with COVID-19 in the first pandemic wave. Methods We analyzed IPC measures taken by hemodialysis centres treating patients presenting with COVID-19 between 1 March 2020 and 31 July 2020 and that completed the European Renal Association COVID-19 Database centre questionnaire. Additionally, we made an inventory of guidelines published in European countries to prevent spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in dialysis centres. Results Data from 73 dialysis units located in and bordering Europe were analyzed. All participating centres implemented IPC measures to mitigate the impact of SARS-CoV-2 during the first pandemic wave. Measures mentioned most often included triage with questions before entering the dialysis ward, measuring body temperature, hand disinfection, masking for all patients and staff, and personal protective equipment for staff members. These measures were also recommended in most of the 14 guidelines that were identified in the inventory of national guidelines and were also scored as being among the most important measures by the authors of this paper. Heterogeneity existed between centres and national guidelines regarding the minimal distance between dialysis chairs and recommendations regarding isolation and cohorting. Conclusions Although variation existed, measures to prevent transmission of SARS-CoV-2 were relatively similar across centres and national guidelines. Further research is needed to assess causal relationships between measures taken and spread of SARS-CoV-2.

Published
2022

20. Expanding the clinical spectrum of self-limiting, rare Kikuchi disease - A case with overwhelming multi-organ involvement.

Author

Hoogstins HA, Kibbelaar RE, Ubels FL, Hemmelder MH, and Hoogendoorn M

Subjects
Blood Chemical Analysis, Female, Histiocytic Necrotizing Lymphadenitis diagnosis, Humans, Middle Aged, Necrosis etiology, Remission, Spontaneous, Histiocytic Necrotizing Lymphadenitis complications, Liver pathology, Lymphohistiocytosis, Hemophagocytic etiology, Multiple Organ Failure etiology, Nephrotic Syndrome etiology
Abstract

Kikuchi disease is a rare disorder with an unknown pathogenesis and a typically self-limiting natural course in predominantly previously healthy young women. Here we present a 54-year-old woman suffering from an overwhelming presentation of Kikuchi disease, associated with haemophagocytic syndrome, liver cell necrosis and nephrotic syndrome. She recovered fully without immunosuppressive treatment. This case report adds to the already broad clinical spectrum of Kikuchi disease described in literature. Awareness among physicians of the full clinical spectrum of Kikuchi disease and the self-limiting nature of this syndrome leads to a good diagnostic approach and may prevent initiation of longstanding immunosuppressive therapy.

Published
2017

21. Safety and long-term effects of renal denervation: Rationale and design of the Dutch registry.

Author

Sanders MF, Blankestijn PJ, Voskuil M, Spiering W, Vonken EJ, Rotmans JI, van der Hoeven BL, Daemen J, van den Meiracker AH, Kroon AA, de Haan MW, Das M, Bax M, van der Meer IM, van Overhagen H, van den Born BJ, van Brussel PM, van der Valk PH, Smak Gregoor PJ, Meuwissen M, Gomes ME, Oude Ophuis T, Troe E, Tonino WA, Konings CJ, de Vries PA, van Balen A, Heeg JE, Smit JJ, Elvan A, Steggerda R, Niamut SM, Peels JO, de Swart JB, Wardeh AJ, Groeneveld JH, van der Linden E, Hemmelder MH, Folkeringa R, Stoel MG, Kant GD, Herrman JP, van Wissen S, Deinum J, Westra SW, Aengevaeren WR, Parlevliet KJ, Schramm A, Jessurun GA, Rensing BJ, Winkens MH, Wierema TK, Santegoets E, Lipsic E, Houwerzijl E, Kater M, Allaart CP, Nap A, and Bots ML

Subjects
Aged, Antihypertensive Agents therapeutic use, Blood Pressure, Female, Humans, Hypertension drug therapy, Male, Middle Aged, Netherlands epidemiology, Preoperative Period, Prospective Studies, Renal Artery innervation, Sympathectomy methods, Time, Treatment Outcome, Hypertension surgery, Registries, Renal Artery surgery, Sympathectomy statistics & numerical data
Abstract

Background: Percutaneous renal denervation (RDN) has recently been introduced as a treatment for therapy-resistant hypertension. Also, it has been suggested that RDN may be beneficial for other conditions characterised by increased sympathetic nerve activity. There are still many uncertainties with regard to efficacy, safety, predictors for success and long-term effects. To answer these important questions, we initiated a Dutch RDN registry aiming to collect data from all RDN procedures performed in the Netherlands., Methods: The Dutch RDN registry is an ongoing investigator-initiated, prospective, multicentre cohort study. Twenty-six Dutch hospitals agreed to participate in this registry. All patients who undergo RDN, regardless of the clinical indication or device that is used, will be included. Data are currently being collected on eligibility and screening, treatment and follow-up., Results: Procedures have been performed since August 2010. At present, data from 306 patients have been entered into the database. The main indication for RDN was hypertension (n = 302, 99%). Patients had a mean office blood pressure of 177/100 (±29/16) mmHg with a median use of three (range 0-8) blood pressure lowering drugs. Mean 24-hour blood pressure before RDN was 157/93 (±18/13) mmHg. RDN was performed with different devices, with the Simplicity™ catheter currently used most frequently., Conclusion: Here we report on the rationale and design of the Dutch RDN registry. Enrolment in this investigator-initiated study is ongoing. We present baseline characteristics of the first 306 participants.

Published
2016

22. [Prevention of contrast nephropathy; guidelines from the Department Nephrology of the University Medical Centre Groningen].

Author

Hemmelder MH, Hoogendoorn M, and Halma C

Subjects
Acidosis, Lactic chemically induced, Humans, Netherlands, Renal Insufficiency chemically induced, Contrast Media adverse effects, Metformin administration & dosage, Metformin adverse effects, Rehydration Solutions therapeutic use, Renal Insufficiency prevention & control, Sodium Chloride therapeutic use
Published
2006

23. A comparison of analytic procedures for measurement of fractional dextran clearances.

Author

Hemmelder MH, de Jong PE, and de Zeeuw D

Subjects
Chromatography, Gel, Chromatography, High Pressure Liquid, Dextrans blood, Dextrans urine, Glomerular Filtration Rate, Humans, Kidney Diseases blood, Proteinuria blood, Sensitivity and Specificity, Dextrans analysis, Kidney Diseases urine, Kidney Glomerulus physiology, Proteinuria urine
Abstract

Fractional dextran clearances have been extensively used to study glomerular size selectivity. We report on an analysis of different laboratory procedures involved in measuring fractional dextran clearances. The deproteinization of plasma samples by 20% trichloroacetic acid (TCA) revealed a protein contamination of 0.2% +/- 0.3%, whereas both 5% TCA and zinc sulfate deproteinization revealed a significantly higher remaining sample protein content (2.5% +/- 0.4% and 3.4% +/- 0.1%, respectively). Only zinc sulfate revealed incomplete deproteinization of urine samples (0.6% +/- 0.2%). Dextran recovery in plasma and urine supernatants was significantly lower after 5% TCA and zinc sulfate deproteinization when compared with 20% TCA deproteinization. Gel permeation chromatography (GPC) and high-performance liquid chromatography (HPLC) showed a variance of calibration smaller than 5% over 1 year. The use of 3 different sets of standard dextrans revealed significant differences in calibration. GPC and HPLC followed by anthrone assay showed a comparable variance in dextran concentration in plasma, from 3 to 6 nm (14% to 25%), whereas the variance in urine was lower for the GPC and anthrone assay, especially from 5.4 to 6 nm (23% to 43% versus 50% to 78%). HPLC and online refractometry showed the lowest variance of dextran concentration in plasma, from 3 to 6 nm (<4%), and in urine, from 3 to 5.2 nm (<7%), whereas it showed a higher variance in urine, from 5.4 to 6 nm, in comparison with GPC and HPLC with the anthrone assay. The GPC and anthrone assay revealed higher fractional dextran clearances in comparison with the HPLC and anthrone assay in healthy subjects (3 to 5.4 nm) as well as in patients with nondiabetic proteinuria (4.2 to 5.8 nm), and lower clearances in patients from 3 to 3.4 nm. The HPLC and anthrone assay revealed higher clearances in comparison with HPLC and online refractometry in healthy subjects (3.6 to 5.4 nm) and in patients (3.6 to 5.2 nm). The GPC and anthrone assay revealed characteristic differences in fractional dextran clearances between healthy subjects and patients. The HPLC and anthrone assay showed no significant differences between both groups, whereas HPLC and online refractometry showed only an increased clearance of dextrans from 4.6 to 5.2 nm in patients. Fractional clearances of dextran 5.6 nm as estimated by all 3 dextran assays were not significantly related to the fractional immunoglobulin G clearance or the immunoglobulin-to-albumin clearance index in our patients. Quantitative and qualitative differences in fractional dextran clearances may be induced by differences in laboratory procedures. We recommend sample preparation by 20% TCA deproteinization, frequent calibration with 1 set of dextran standards with low polydispersity, size-exclusion chromatography by GPC, and dextran detection by anthrone assay for optimal measurement of fractional dextran clearances. Even with such an approach, however, the variability in the measurement remains extremely high in the important range of dextrans greater than 5 nm.

Published
1998
Full Text
View/download PDF

24. Measurement of glomerular charge selectivity in non-diabetic renal disease.

Author

Hemmelder MH, de Zeeuw D, and de Jong PE

Subjects
Adult, Aged, Albuminuria metabolism, Albuminuria urine, Amylases metabolism, Amylases urine, Electrophysiology, Female, Humans, Immunoglobulin G metabolism, Immunoglobulin G urine, Male, Middle Aged, Pancreas metabolism, Reference Values, Saliva metabolism, Kidney Diseases metabolism, Kidney Diseases physiopathology, Kidney Glomerulus metabolism, Kidney Glomerulus physiopathology
Abstract

Background: Until now, the renal clearance index of IgG to IgG4 (IgG/IgG4) as well as pancreatic to salivary amylase (PA/SA) were separately used as parameters of renal charge selectivity in diabetic and non-diabetic albuminuria. The suitability of the IgG index may be questioned because urinary loss of IgG rather reflects a size selective defect. In contrast, the amylase index seems more appropriate to reflect renal charge selectivity because its molecular size is comparable to albumin. We questioned whether IgG/IgG4 and PA/SA reflect renal charge selectivity in a comparable way in subjects with non-diabetic albuminuria over a wide range., Methods: Renal fractional clearances of albumin, IgG, IgG4, PA and SA were estimated from ambulatory 24-h urine samples in 12 subjects with normo-albuminuria (UAE 4 [3-17] micrograms/min), six with micro-albuminuria (UAE: 147[36-200] micrograms/min), and 20 with macro-albuminuria (UAE: 2301 [608-13611] micrograms/min)., Results: Macro-albuminuria is associated with a reduced IgG/IgG4 and PA/SA, whereas micro-albuminuria is only associated with a reduced IgG/IgG4 compared to normo-albuminuria. A reduction of IgG/IgG4 (r = -0.75, P < 0.001) and PA/SA (r = -0.52, P < 0.001) correlates with an increased albuminuria. In addition, IgG/IgG4 correlates with PA/SA in the total population (r = 0.49, P < 0.01). IgG/IgG4 (r = 0.51, P < 0.05) correlates with the size selective index IgG/albumin in an opposite way to PA/SA (r = -0.52, P < 0.05) in 20 subjects with macro-albuminuria. Multiple regression analysis revealed IgG clearance to be the variable which contributes to the variance of albuminuria clearance for the greater part in our population., Conclusion: Both charge selective indices do not appear to correlate in micro-albuminuria. In addition, the presence of a size selective defect has a opposing effect on both charge selective indices. Although the reduction of IgG/IgG4 and PA/SA with increasing albuminuria suggests a progressive charge selective defect, albuminuria in our population is almost entirely explained by urinary loss of IgG. These data seriously question whether either one or both charge selective indices IgG/IgG4 and PA/SA do specifically reflect glomerular charge selectivity.

Published
1997

25. Is the antiproteinuric response to inhibition of the renin-angiotensin system less effective during the night?

Author

Buter H, Hemmelder MH, van Paassen P, Navis G, de Zeeuw D, and de Jong PE

Subjects
Adult, Blood Pressure drug effects, Female, Humans, Male, Middle Aged, Proteinuria urine, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Antihypertensive Agents therapeutic use, Circadian Rhythm, Imidazoles therapeutic use, Indoles therapeutic use, Proteinuria drug therapy, Renin antagonists & inhibitors, Renin-Angiotensin System drug effects
Abstract

Background: In glomerular disease proteinuria usually has a circadian pattern with maximum excretion during the day. Blockade of the renin-angiotensin system (RAS) results in a 50% reduction of proteinuria as measured in 24-h urine collections. We questioned whether anti-proteinuric treatment by blockade of the RAS is as effective during the day as during the night., Methods: We analysed data from two intervention studies on proteinuria in patients with non-diabetic renal disease. In the first study, six hospitalized patients (proteinuria 5.8 +/- 2.9 g/day) were treated with the renin-inhibitor remikiren 600 mg o.d. during 8 days. In the second study eight ambulant patients (proteinuria 7.5 +/- 2.7 g/day) were treated during 6 weeks with the ACE-inhibitor trandolapril 4 mg o.d. Urine was collected in a day- and in a night-time portion., Results: Daytime proteinuria declined from 0.29 +/- 0.15 to 0.22 +/- 0.11 g/h (P < 0.05) during remikiren and from 0.33 +/- 0.14 to 0.16 +/- 0.08 g/h (P < 0.05) during trandolapril. Night-time proteinuria, however, was not significantly reduced from 0.23 +/- 0.11 to 0.19 +/- 0.11 g/h during remikiren and from 0.29 +/- 0.17 to 0.20 +/- 0.12 g/h during trandolapril. Both interventions effectively lowered blood pressure during the day as well as the night., Conclusion: In both studies relative nocturnal therapy resistance to the antiproteinuric effect of RAS blockade was found, despite 24-h efficacy of blood pressure effect. This may have clinical relevance because it contributes to rest-proteinuria and thus may affect long term renal function outcome. It may be worthwhile to explore alternative therapeutic regimens to improve the nocturnal antiproteinuric response.

Published
1997

26. Blood pressure reduction initiates the antiproteinuric effect of ACE inhibition.

Author

Hemmelder MH, de Zeeuw D, Gansevoort RT, and de Jong PE

Subjects
Adult, Blood Pressure drug effects, Cross-Over Studies, Drug Therapy, Combination, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Proteinuria drug therapy, Single-Blind Method, Angiotensin II administration & dosage, Enalaprilat administration & dosage, Nitroprusside administration & dosage, Proteinuria physiopathology, Vasoconstrictor Agents administration & dosage, Vasodilator Agents administration & dosage
Abstract

Several observations question the role of blood pressure and renal hemodynamic changes in the long-term antiproteinuric effect of ACE inhibition. To differentiate blood pressure and renal effects in the initial antiproteinuric response, the placebo-controlled acute effects of the ACE inhibitor enalaprilat (10 mg i.v.) on blood pressure, renal hemodynamics, and proteinuria were compared with those of nitroprusside in nine patient with non-diabetic proteinuria. In addition, we studied whether an exogenous angiotensin II infusion reverse the initial enalaprilat-induced antiproteinuric response. Enalaprilat and nitroprusside reduced MAP by -11.3 +/- 2.4% and -14.1 +/- 2.3%, respectively, whereas only enalaprilat showed renal hemodynamic effects, reflected by an increase in ERPF of 18.4 +/- 5.4% and a decrease in FF of -17.1 +/- 2.6%. Despite the contrasting renal hemodynamic profiles, enalaprilat (-10.6 +/- 4.8%) and nitroprusside (-12.8 +/- 5.1% equally decreased proteinuria. Exogenous infusion of angiotensin II completely reversed the blood pressure reduction and renal efferent vasodilatation induced by enalaprilat. proteinuria also increased by 13.1 +/- 7.8% to placebo level, albeit statistically non-significant. We conclude that the initial antiproteinuric effect of ACE inhibition appears to be mediated by blood pressure reduction and does not require its specific renal hemodynamic effect. Further studies should clarify whether the renal efferent vasodilatation during ACE inhibition is required to gradually induce renal structural changes that prevent the abundant passage of proteins.

Published
1996
Full Text
View/download PDF

27. Proteinuria: a risk factor for pregnancy-related renal function decline in primary glomerular disease?

Author

Hemmelder MH, de Zeeuw D, Fidler V, and de Jong PE

Subjects
Adolescent, Adult, Blood Pressure, Creatinine blood, Female, Humans, Kidney Diseases complications, Kidney Glomerulus, Pregnancy, Regression Analysis, Retrospective Studies, Risk Factors, Kidney physiopathology, Kidney Diseases physiopathology, Pregnancy Complications physiopathology, Proteinuria etiology
Abstract

Pregnancy may be followed by a postpartum acceleration of renal function loss in patients with renal disease. We retrospectively analyzed the effects of pregnancy on progressive renal function decline, and the risk factors for an acceleration, in a group of 19 renal disease patients with 30 pregnancies and a group of 31 patients who did not become pregnant after onset of glomerular disease. The rate of renal function loss was calculated for each patient by linear regression on reciprocal serum creatinine values over 11 years' follow-up. Multiple regression analysis showed that both pregnancy (P = 0.03) and initial proteinuria (P = 0.005) were independently related with the rate of renal function loss. Such a relation could not be observed with histologic diagnosis, and initial age, renal function, blood pressure, and serum albumin. Further analysis showed that 10 of 30 pregnancies are followed by a predefined acceleration of renal function loss. These pregnancies were preceded and complicated by a higher proteinuria (4.1 v 1.7 g/d, P < 0.005; and 3.6 v 2.1 g/d, P < 0.05, respectively) compared with the other 20 pregnancies that are not followed by such an acceleration. In conclusion, patients with primary glomerular disease complicated by substantial proteinuria are at risk for acceleration of renal function decline after pregnancy.

Published
1995
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results